SES
19.11.2021 08:52:13 CET | Business Wire | Press release
Residents of two remote Kazakhstan villages can now benefit from unprecedented Internet speeds via satellite-enabled Wi-Fi, through a network set up for 30 days by the leading global content connectivity solutions provider SES. The demo is implemented in cooperation with the Republican Center for Space Communications (RCSC ), a subsidiary of the Ministry of Digital Development, Innovations and Aerospace Industry and AsiaNetCom, a Kazakhstan-based connectivity provider. During the demonstration, the companies have achieved 380Mbps downlink and 120Mbps uplink via SES’s O3b satellite constellation, the highest speed ever recorded in Kazakhstan via satellite.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211118006475/en/
The demo is done in the framework of the country’s national project called “Technological breakthrough via digitalisation, science and innovation”, that aims to bridge the digital divide and bring the benefits of high-performance communication networks for healthcare, businesses, local administrations, education and more.
As part of the collaboration agreement between SES and RCSC signed earlier this year, the test demonstrates the benefits of SES’s Medium Earth Orbit (MEO) networks and its upcoming second-generation O3b mPOWER communications system.
The current demo network is leveraging SES’s first-generation O3b satellites to connect an RCSC teleport located in Kokterek with the villages of Akterek and Beriktas for high-speed Internet access.
“Kazakhstan has already made progress in providing Internet connectivity to the population. However, there are still remote villages where it is impossible to deliver a network using radio relay communications or through cable connection. In those circumstances, we decided to use satellite constellations. This will allow us to expand our coverage and provide broadband Internet connection to the population of Kazakhstan”, said Bagdat Mussin, Minister of Digital Development, Innovations and Aerospace Industry (MDDIAI RK).
“The premise of national project “Technological breakthrough via digitalisation, science and innovation” is to bring the same quality of life and opportunities afforded by Internet access to every citizen of the country, wherever they live - in Nur-Sultan or in a remote mountain village. In some cases, the use of terrestrial networks is economically impractical, and we are considering the opportunities to implement innovative satellite technology to provide high-speed connectivity in those remote villages. The demo gives us an opportunity to explore the possibilities of further scaling”, said Malik Zhuiriktayev, Chairman of the Board of JSC RCSC.
“We are very excited to participate in this project, which aims to digitalise and to improve all spheres of life and economy in the country. Today in collaboration with our partners RCSC and AsiaNetCom, we have demonstrated the unrivalled performance of our innovative and proven MEO network by connecting rural Kazakhstan”, said Sandeep Jalan, Chief Financial Officer of SES. “When operational next year, our second-generation MEO system, O3b mPOWER, will further multiply the capacity delivered and bandwidth. In addition, it will deliver significantly higher speeds flexibly, catering to the increasing needs from governments, enterprises and mobile operators.”
Follow us on:
Twitter
Facebook
YouTube
LinkedIn
Instagram
Read our Blogs >
Visit the Media Gallery >
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,500 channels and has an unparalleled reach of 361 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .
About RCSC
Joint Stock Company "Republican Center for Space Communication" was established by the Decree of the Government of the Republic of Kazakhstan in December 2003 on behalf of the First President of the Republic of Kazakhstan.
JSC "RCSC" is a subordinate enterprise of the Aerospace Committee of the Ministry of Digital Development, Innovation and Aerospace Industry of the Republic of Kazakhstan, the National Operator of the Space Communication System of Kazakhstan.
The Republican Center for Space Communications provides services for the provision of the transponder capacity of spacecraft (SC) of the KazSat series, monitoring of fixed satellite communication channels in the Ku-band on a geostationary arc from 13 to 130 E, as well as using the capabilities of the Teleport based on the Reserve ground-based spacecraft control complex and communication monitoring systems.
The resources of the KazSat series spacecraft made it possible to implement efficient and reliable satellite communication channels in the Republic of Kazakhstan. Spacecraft of the KazSat series, operated by RCKS JSC, provide great opportunities for telecommunications operators in Kazakhstan, national companies and holdings, government agencies and private companies for organizing digital TV and radio broadcasting (HD, DTH, IPTV), broadband Internet access, data transmission and creation of corporate satellite communication networks of various topologies.
Currently, JSC "RCSC" is one of the leading enterprises in the implementation of activities on communications in the telecommunications market of Kazakhstan.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211118006475/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom